Analysts Anticipate Iovance Biotherapeutics Inc (IOVA) Will Announce Earnings of -$0.29 Per Share
Brokerages expect that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will report earnings per share (EPS) of ($0.29) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings. The lowest EPS estimate is ($0.37) and the highest is ($0.18). Iovance Biotherapeutics posted earnings per share of ($0.26) during the same quarter last year, which would indicate a negative year-over-year growth rate of 11.5%. The firm is expected to announce its next earnings results on Thursday, May 9th.
On average, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($1.22) per share for the current financial year, with EPS estimates ranging from ($1.47) to ($0.72). For the next fiscal year, analysts expect that the business will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.69) to ($0.77). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that cover Iovance Biotherapeutics.
IOVA has been the subject of several recent research reports. Oppenheimer set a $25.00 target price on Iovance Biotherapeutics and gave the company a “buy” rating in a report on Friday, January 11th. B. Riley initiated coverage on Iovance Biotherapeutics in a report on Monday, December 31st. They set a “buy” rating and a $24.00 target price for the company. Robert W. Baird initiated coverage on Iovance Biotherapeutics in a report on Wednesday, February 6th. They set an “outperform” rating and a $29.00 target price for the company. BidaskClub raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Thursday, April 4th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Iovance Biotherapeutics in a report on Tuesday, April 2nd. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $22.86.
A number of hedge funds have recently modified their holdings of the stock. Advisor Group Inc. increased its stake in shares of Iovance Biotherapeutics by 58.6% in the fourth quarter. Advisor Group Inc. now owns 8,118 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 3,000 shares during the last quarter. Kalos Management Inc. acquired a new position in Iovance Biotherapeutics during the fourth quarter worth $93,000. Virtu Financial LLC acquired a new position in Iovance Biotherapeutics during the first quarter worth $99,000. Great West Life Assurance Co. Can increased its position in Iovance Biotherapeutics by 67.4% during the fourth quarter. Great West Life Assurance Co. Can now owns 14,538 shares of the biotechnology company’s stock worth $124,000 after buying an additional 5,853 shares during the last quarter. Finally, Amalgamated Bank acquired a new position in Iovance Biotherapeutics during the fourth quarter worth $130,000. 95.92% of the stock is owned by institutional investors and hedge funds.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
See Also: Blue-Chip Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.